Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study.

BACKGROUND Smoking is a potent risk factor for coronary artery disease; however, prior studies describe increased platelet inhibition with clopidogrel among smokers, and some studies report improved outcomes among smokers, a finding described as the smoker's paradox. This study assessed the relationship between platelet reactivity and clinical outcomes after percutaneous coronary interventions among current smokers and nonsmokers. METHODS ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a prospective, multicenter registry of patients treated with coronary drug-eluting stents. Platelet reactivity was assessed by the VerifyNow point-of-care assay; high on-treatment platelet reactivity (HPR) was defined as P2Y12 reaction units >208. A propensity-adjusted multivariable analysis was performed to determine the relationship between current smoking, platelet reactivity, and subsequent adverse events. RESULTS Among 8582 patients, 22.6% were active smokers at the time of their percutaneous coronary intervention procedure. Current smokers were younger and had fewer comorbidities compared with nonsmokers. Current smokers had lower mean P2Y12 reaction units and lower rates of HPR compared with nonsmokers. Current smokers had similar rates of adverse events compared with nonsmokers. HPR was associated with higher rates of adverse events for both smokers and nonsmokers; however, there was evidence of interaction between smoking status and the effect of HPR. Smokers with HPR had significantly higher rates of stent thrombosis. Adverse event rates were highest among current smokers with HPR. CONCLUSIONS Current smoking was associated with lower P2Y12 reaction units and lower rates of HPR on average; however, the combination of current smoking and HPR was associated with high rates of stent thrombosis. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT00638794.

[1]  T. Bergmeijer,et al.  The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions , 2017, Journal of thrombosis and haemostasis : JTH.

[2]  Yun Gi Kim,et al.  Cigarette Smoking Does Not Enhance Clopidogrel Responsiveness After Adjusting VerifyNow P2Y12 Reaction Unit for the Influence of Hemoglobin Level. , 2016, JACC. Cardiovascular interventions.

[3]  D. Sibbing,et al.  Smoking and Clopidogrel Response Revisited: Hemoglobin Levels Explaining the Smoker's Paradox. , 2016, JACC. Cardiovascular interventions.

[4]  Deepak L. Bhatt,et al.  Smoker's Paradox in Patients With ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention , 2016, Journal of the American Heart Association.

[5]  Yun Gi Kim,et al.  Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry , 2014, PloS one.

[6]  D. Prabhakaran,et al.  Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. , 2014, American heart journal.

[7]  J. Rade,et al.  Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness , 2013, Journal of thrombosis and haemostasis : JTH.

[8]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[9]  T. Nolin,et al.  The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. , 2013, Journal of the American College of Cardiology.

[10]  Si‐Hyuck Kang,et al.  Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of ‘smokers’ paradox' , 2012, Heart.

[11]  L. Wallentin,et al.  Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2012, American heart journal.

[12]  Hae-Young Lee,et al.  Enhanced Clopidogrel Responsiveness in Smokers: Smokers' Paradox Is Dependent on Cytochrome P450 CYP1A2 Status , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[13]  B. Baker,et al.  The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. , 2008, Journal of the American College of Cardiology.

[14]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[15]  J. J. Griffin,et al.  Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. , 2005, American heart journal.

[16]  I. Ockene,et al.  Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[17]  M. Ishihara,et al.  Clinical implications of cigarette smoking in acute myocardial infarction: acute angiographic findings and long-term prognosis. , 1997, American heart journal.

[18]  D. Nordenberg,et al.  The effect of cigarette smoking on hemoglobin levels and anemia screening. , 1990, JAMA.

[19]  E. Gilpin,et al.  Smoking status at the time of acute myocardial infarction and subsequent prognosis. , 1985, American heart journal.